Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Helius Medical Technologies ( (HSDT) ) just unveiled an announcement.
On September 15, 2025, Helius Medical Technologies, Inc. entered into a Sales Agreement with Clear Street LLC and Maxim Group LLC to offer and sell shares of its Class A common stock, with a potential aggregate sales price of up to $92.8 million. This agreement follows the termination of a previous sales agreement with Roth Capital Partners, LLC. The company has also agreed to pay commissions to the agents and cover certain legal expenses. Additionally, at a special meeting on May 23, 2025, stockholders approved an increase in the number of authorized shares of common stock to 800 million.
The most recent analyst rating on (HSDT) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
Spark’s Take on HSDT Stock
According to Spark, TipRanks’ AI Analyst, HSDT is a Underperform.
Helius Medical Technologies faces significant financial challenges, with declining revenue and ongoing losses being the most impactful factors. The technical analysis indicates a bearish trend, and the valuation metrics are unattractive due to negative earnings. The absence of earnings call data and corporate events further limits the potential for a positive outlook.
To see Spark’s full report on HSDT stock, click here.
More about Helius Medical Technologies
Average Trading Volume: 401,505
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.14M
See more data about HSDT stock on TipRanks’ Stock Analysis page.